GOREISAN for Heart Failure (GOREISAN-HF) Trial

Phase 4Active Not RecruitingNCT04691700

Takeshi Morimoto1,179 enrolled

Overview

The objective of the GOREISAN-HF trial is to assess the effect of the administration of Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume overload.

Current guidelines recommend the use of loop diuretics as an indication for class I to improve HF symptoms regardless of left ventricular ejection fraction. Loop diuretics, however, are known to activate the renin-angiotensin-aldosterone system and the sympathetic nervous system, which could accelerate HF progression. Loop diuretics could also cause worsening renal function and electrolyte disturbance, and it is desirable to have an alternative drug to loop diuretics to effectively relieve congestive symptoms. Goreisan (TJ-17), a traditional Japanese medicine composed of five herbal medicines, has long been used in Japan to treat impairments of the regulation of body fluid homeostasis, including edema, and has been less likely to cause renal dysfunction and electrolyte abnormalities. We therefore planned a multicenter, randomized, interventional, parallel assignment, open-label treatment trial to evaluate the long-term effect of in-hospital initiation of Goreisan, when added to standard therapy, in patients with worsening congestive heart failure and clear signs of volume overload.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,179

Conditions

Heart Failure Edema Traditional Japanese Medicine Kampo Medicine Clinical Trial

Interventions

GoreisanDRUG

Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics

Standard TreatmentDRUG

Standard therapy without Goreisan

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed congestive heart failure (CHF) by Framingham criteria * CHF patients with cardiac edema and signs due to cardiac edema (signs of fluid overload: lower limb edema, pulmonary effusion, or pulmonary congestion on chest x-ray) * Elevated N-terminal pro brain-type natriuretic peptide (NT-proBNP) ≥300 pg/mL or brain natriuretic peptide (BNP) ≥100 pg/mL at enrollment * Patients ≥ 20 years of age, male or female * Provision of signed informed consent before any assessment is performed Exclusion Criteria: * Valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization * Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to enrollment or intent to implant a CRT device * Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization * End-stage renal failure (estimated glomerular filtration rate \[eGFR\] \<15 mL/min/1.73m2) at enrollment * Patients who are expected to have a life expectancy of 6 months or less * Acute coronary syndrome at screening * Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization * Treatment with herbal medicine at enrollment * Confirmed poor tolerability of Goreisan (including cinnamon allergy) * Considered not appropriate for the participation of the study

Locations (1)

Kyoto University Graduate School of Medicine

Kyoto, Kyoto, Japan

Outcomes

Primary Outcomes

Improvement of cardiac edema

Cardiac edema is defined as conditions having one or more following conditions: lower limb edema, pleural effusion, or pulmonary congestion on chest x-ray. Lower limb edema, pleural effusion, and pulmonary congestion are assessed by investigators. Improvement is defined as the disappearance of all signs of cardiac edema.

Time frame: 1 year

Composite endpoint of all-cause death or hospitalization

Composite of death from any cause or hospitalization from any cause.

Time frame: 3 years

Secondary Outcomes

Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score

The KCCQ is a validated self-administered instrument of quality of life and health status in heart failure (HF) patients. The clinical summary score is a composite assessment of physical limitation, total symptom score, health-related quality of life, and social limitation scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

Time frame: 6 months

Change in loop diuretics dose

Loop diuretic dose will be calculated as furosemide-equivalent dose.

Time frame: 6 months

Change in loop diuretics dose

Loop diuretic dose will be calculated as furosemide-equivalent dose.

Time frame: 1 year

Composite endpoint of sustained decline in eGFR ≥50%, ESRD (end stage renal disease) or renal death

End Stage Renal Disease (ESRD) is defined as: Sustained eGFR \<15 mL/min/1.73m2, Chronic dialysis treatment or, receiving a renal transplant. Renal death is defined as renal failure as the underlying cause of death.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.